Identification and validation of Sertoli cell homing peptides as molecular steering for testis targeted drug delivery
The testicle, an organ privileged with immunity because of Blood-Testis Barrier (BTB), poses a major impediment to developing and delivering drugs to the testes. These problems can be prevented by targeting testicular cells using specific ligands, such as homing peptides. This is the first study to...
Uloženo v:
| Vydáno v: | Journal of drug targeting Ročník 31; číslo 4; s. 390 - 401 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Taylor & Francis
21.04.2023
|
| Témata: | |
| ISSN: | 1061-186X, 1029-2330, 1029-2330 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The testicle, an organ privileged with immunity because of Blood-Testis Barrier (BTB), poses a major impediment to developing and delivering drugs to the testes. These problems can be prevented by targeting testicular cells using specific ligands, such as homing peptides. This is the first study to demonstrate the successful selection of Sertoli cell homing peptides using a phage display peptide library. The identification of peptides is performed with Sanger sequencing and high-throughput NGS. The Sertoli cell and testis targeting potential of the SCHP1 and SCHP2 was confirmed using confocal microscopy and flow cytometry of the FITC-labelled peptides and in vivo bio-distribution of the corresponding Cy5.5-tagged peptides. Secondary structures were predicted in the setting of different polarity by circular dichroism. The results suggest that SCHP1 and SCHP2 can effectively target Sertoli cells. In vivo bio-distribution in mouse models indicated significantly higher uptake of SCHP1 and SCHP2 by testes compared with the heart, brain, and spleen. SCHP1 and SCHP2 can be adopted as molecular steering for targeted male contraceptive delivery, treatment of testicular cancer, and male infertility. Further development of the peptides into peptidomimetics may increase their stability, and information on the molecular targets of these peptides may reveal their therapeutic potential. |
|---|---|
| AbstractList | The testicle, an organ privileged with immunity because of Blood-Testis Barrier (BTB), poses a major impediment to developing and delivering drugs to the testes. These problems can be prevented by targeting testicular cells using specific ligands, such as homing peptides. This is the first study to demonstrate the successful selection of Sertoli cell homing peptides using a phage display peptide library. The identification of peptides is performed with Sanger sequencing and high-throughput NGS. The Sertoli cell and testis targeting potential of the SCHP1 and SCHP2 was confirmed using confocal microscopy and flow cytometry of the FITC-labelled peptides and
bio-distribution of the corresponding Cy5.5-tagged peptides. Secondary structures were predicted in the setting of different polarity by circular dichroism. The results suggest that SCHP1 and SCHP2 can effectively target Sertoli cells.
bio-distribution in mouse models indicated significantly higher uptake of SCHP1 and SCHP2 by testes compared with the heart, brain, and spleen. SCHP1 and SCHP2 can be adopted as molecular steering for targeted male contraceptive delivery, treatment of testicular cancer, and male infertility. Further development of the peptides into peptidomimetics may increase their stability, and information on the molecular targets of these peptides may reveal their therapeutic potential. The testicle, an organ privileged with immunity because of Blood-Testis Barrier (BTB), poses a major impediment to developing and delivering drugs to the testes. These problems can be prevented by targeting testicular cells using specific ligands, such as homing peptides. This is the first study to demonstrate the successful selection of Sertoli cell homing peptides using a phage display peptide library. The identification of peptides is performed with Sanger sequencing and high-throughput NGS. The Sertoli cell and testis targeting potential of the SCHP1 and SCHP2 was confirmed using confocal microscopy and flow cytometry of the FITC-labelled peptides and in vivo bio-distribution of the corresponding Cy5.5-tagged peptides. Secondary structures were predicted in the setting of different polarity by circular dichroism. The results suggest that SCHP1 and SCHP2 can effectively target Sertoli cells. In vivo bio-distribution in mouse models indicated significantly higher uptake of SCHP1 and SCHP2 by testes compared with the heart, brain, and spleen. SCHP1 and SCHP2 can be adopted as molecular steering for targeted male contraceptive delivery, treatment of testicular cancer, and male infertility. Further development of the peptides into peptidomimetics may increase their stability, and information on the molecular targets of these peptides may reveal their therapeutic potential. The testicle, an organ privileged with immunity because of Blood-Testis Barrier (BTB), poses a major impediment to developing and delivering drugs to the testes. These problems can be prevented by targeting testicular cells using specific ligands, such as homing peptides. This is the first study to demonstrate the successful selection of Sertoli cell homing peptides using a phage display peptide library. The identification of peptides is performed with Sanger sequencing and high-throughput NGS. The Sertoli cell and testis targeting potential of the SCHP1 and SCHP2 was confirmed using confocal microscopy and flow cytometry of the FITC-labelled peptides and in vivo bio-distribution of the corresponding Cy5.5-tagged peptides. Secondary structures were predicted in the setting of different polarity by circular dichroism. The results suggest that SCHP1 and SCHP2 can effectively target Sertoli cells. In vivo bio-distribution in mouse models indicated significantly higher uptake of SCHP1 and SCHP2 by testes compared with the heart, brain, and spleen. SCHP1 and SCHP2 can be adopted as molecular steering for targeted male contraceptive delivery, treatment of testicular cancer, and male infertility. Further development of the peptides into peptidomimetics may increase their stability, and information on the molecular targets of these peptides may reveal their therapeutic potential.The testicle, an organ privileged with immunity because of Blood-Testis Barrier (BTB), poses a major impediment to developing and delivering drugs to the testes. These problems can be prevented by targeting testicular cells using specific ligands, such as homing peptides. This is the first study to demonstrate the successful selection of Sertoli cell homing peptides using a phage display peptide library. The identification of peptides is performed with Sanger sequencing and high-throughput NGS. The Sertoli cell and testis targeting potential of the SCHP1 and SCHP2 was confirmed using confocal microscopy and flow cytometry of the FITC-labelled peptides and in vivo bio-distribution of the corresponding Cy5.5-tagged peptides. Secondary structures were predicted in the setting of different polarity by circular dichroism. The results suggest that SCHP1 and SCHP2 can effectively target Sertoli cells. In vivo bio-distribution in mouse models indicated significantly higher uptake of SCHP1 and SCHP2 by testes compared with the heart, brain, and spleen. SCHP1 and SCHP2 can be adopted as molecular steering for targeted male contraceptive delivery, treatment of testicular cancer, and male infertility. Further development of the peptides into peptidomimetics may increase their stability, and information on the molecular targets of these peptides may reveal their therapeutic potential. |
| Author | Jirwankar, Yugandhara Dighe, Vikas |
| Author_xml | – sequence: 1 givenname: Yugandhara orcidid: 0000-0002-6196-1687 surname: Jirwankar fullname: Jirwankar, Yugandhara organization: National Centre for Preclinical Reproductive and Genetic Toxicology, ICMR - National Institute for Research in Reproductive and Child Health – sequence: 2 givenname: Vikas orcidid: 0000-0001-9718-7358 surname: Dighe fullname: Dighe, Vikas organization: National Centre for Preclinical Reproductive and Genetic Toxicology, ICMR - National Institute for Research in Reproductive and Child Health |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36604336$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUU2PFCEQJWaN-6E_QcPRS48FdNPd8aLZ-LHJJh7UxBthoBgxNIxAr5l_b7czc_Ggp6oK772i3rsmFzFFJOQ5gw2DAV4xkIwN8tuGA-cbzmQL0D8iVwz42HAh4GLtJWtW0CW5LuUHABOSwRNyKaSEVgh5ReY7i7F6542uPkWqo6UPOnh7HJOjnzHXFDw1GAL9niYfd3SP--otFqoLnVJAMwedaamIeX12KdOKpfpCq847rGipzfOOWgz-AfPhKXnsdCj47FRvyNf3777cfmzuP324u31735iWidpY0WtpR8NxtA6Wq9G1gO3Ixt4OvLNslNgbMFxut8PY62WQrOvQQWe7cUBxQ14edfc5_ZyXH6nJl_UQHTHNRfFeLlqSi26BvjhB5-2EVu2zn3Q-qLNVC-D1EWByKiWjU8bXPy7VrH1QDNQajDoHo9Zg1CmYhd39xT4v-B_vzZHn4-LqpH-lHKyq-hBSdllH44sS_5b4Ddefpj4 |
| CitedBy_id | crossref_primary_10_1002_smll_202307111 crossref_primary_10_3389_fmicb_2025_1571679 |
| Cites_doi | 10.1016/j.urology.2006.02.045 10.1080/1061186031000086063 10.1038/380364a0 10.1007/s40005-017-0374-0 10.1016/S0066-4103(08)00201-9 10.1007/978-1-60327-569-9_18 10.1126/science.4001944 10.2174/0929867323666160112122724 10.1039/c0ib00013b 10.1021/acs.chemrev.9b00008 10.1161/CIRCULATIONAHA.104.529537 10.1056/NEJMra1407550 10.1093/nar/gkv1100 10.1016/j.chroma.2019.04.037 10.1016/j.jviromet.2017.11.012 10.1038/nm0202-121 10.7150/ijbs.31957 10.1007/978-1-4939-0659-8_18 10.1016/j.ucl.2013.08.012 10.1055/s-0036-1571435 10.1073/pnas.251687998 10.1055/s-0034-1375184 10.1002/j.1939-4640.2004.tb02780.x 10.1016/j.juro.2015.03.076 10.1101/pdb.prot093419 10.1186/gb-2007-8-2-r24 10.1002/med.20225 10.1074/jbc.274.17.11593 10.2174/1573413052953110 10.3109/1061186X.2011.572974 10.1007/s13346-011-0039-x 10.1080/1061186X.2018.1531419 10.1038/nm1048 10.1038/nrurol.2011.26 10.1371/journal.pone.0012252 10.1016/j.drudis.2014.10.003 10.1002/ijc.20931 10.1093/bioinformatics/btab203 10.1007/978-1-4939-2020-4_17 |
| ContentType | Journal Article |
| Copyright | 2023 Informa UK Limited, trading as Taylor & Francis Group 2023 |
| Copyright_xml | – notice: 2023 Informa UK Limited, trading as Taylor & Francis Group 2023 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1080/1061186X.2022.2164007 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1029-2330 |
| EndPage | 401 |
| ExternalDocumentID | 36604336 10_1080_1061186X_2022_2164007 2164007 |
| Genre | Research Article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 00X 03L 0R~ 29K 36B 4.4 53G 5GY AAGDL AALUX AAMIU AAPUL AAQRR ABBKH ABDBF ABEIZ ABJNI ABLIJ ABLKL ABUPF ABWVI ABXYU ACENM ACGEJ ACGFS ACIEZ ACUHS ADCVX ADRBQ ADXPE AECIN AENEX AEOZL AFKVX AFRVT AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AQTUD BABNJ BLEHA BOHLJ CCCUG CS3 D-I DKSSO EAP EBC EBD EBS EMB EMK EMOBN EPL ESX F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- RNANH RVRKI SV3 TASJS TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TUS UHWXJ V1S ~1N AAYXX CITATION 0BK 0VX 5VS AACCU AALIY AAPXX ABCRQ ACKYO ADYSH AFAUU AFQCT AGAFX AJEBJ AJXHO AWYRJ BVLLS CAG CGR COF CUY CVF DEIEU DLVIE DTRLO DZHFC ECM EIF EJD JFOCU M44 NPM NUSFT QRXOQ 7X8 |
| ID | FETCH-LOGICAL-c413t-d37a6d9c2e9df0080ef40e49197d825d196e7c0c26bb897ae7c6155ef05d598e3 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000912744600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1061-186X 1029-2330 |
| IngestDate | Tue Aug 05 10:51:00 EDT 2025 Wed Feb 19 02:24:15 EST 2025 Sat Nov 29 04:25:30 EST 2025 Tue Nov 18 22:31:39 EST 2025 Mon Oct 20 23:46:03 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | drug targeting Sertoli cell biopanning testis phage display Homing peptides |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c413t-d37a6d9c2e9df0080ef40e49197d825d196e7c0c26bb897ae7c6155ef05d598e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-9718-7358 0000-0002-6196-1687 |
| OpenAccessLink | https://figshare.com/articles/journal_contribution/Identification_and_validation_of_Sertoli_cell_homing_peptides_as_molecular_steering_for_testis_targeted_drug_delivery/21825368 |
| PMID | 36604336 |
| PQID | 2761976235 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2761976235 pubmed_primary_36604336 informaworld_taylorfrancis_310_1080_1061186X_2022_2164007 crossref_citationtrail_10_1080_1061186X_2022_2164007 crossref_primary_10_1080_1061186X_2022_2164007 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-04-21 |
| PublicationDateYYYYMMDD | 2023-04-21 |
| PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of drug targeting |
| PublicationTitleAlternate | J Drug Target |
| PublicationYear | 2023 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | CIT0030 CIT0010 CIT0031 CIT0012 CIT0034 CIT0011 CIT0033 Crosnoe LE (CIT0004) 2013; 2 CIT0014 CIT0036 CIT0013 CIT0035 CIT0016 CIT0038 CIT0015 CIT0037 CIT0018 CIT0017 CIT0039 CIT0019 Work LM (CIT0032) 2005; 108 CIT0041 CIT0040 CIT0021 CIT0043 CIT0020 CIT0042 CIT0001 CIT0023 CIT0022 Ehrlich Y (CIT0008) 2015; 4 CIT0025 CIT0002 CIT0024 CIT0005 CIT0027 Cocuzza M (CIT0003) 2007; 1 CIT0026 CIT0007 CIT0029 Garza AZ (CIT0044) 2022 CIT0006 CIT0028 CIT0009 |
| References_xml | – ident: CIT0006 doi: 10.1016/j.urology.2006.02.045 – ident: CIT0017 doi: 10.1080/1061186031000086063 – volume: 4 start-page: 381 issue: 3 year: 2015 ident: CIT0008 publication-title: Transl Androl Urol – ident: CIT0014 doi: 10.1038/380364a0 – ident: CIT0026 doi: 10.1007/s40005-017-0374-0 – ident: CIT0043 doi: 10.1016/S0066-4103(08)00201-9 – ident: CIT0031 doi: 10.1007/978-1-60327-569-9_18 – ident: CIT0016 doi: 10.1126/science.4001944 – ident: CIT0012 doi: 10.2174/0929867323666160112122724 – ident: CIT0042 doi: 10.1039/c0ib00013b – ident: CIT0041 doi: 10.1021/acs.chemrev.9b00008 – ident: CIT0024 doi: 10.1161/CIRCULATIONAHA.104.529537 – ident: CIT0007 doi: 10.1056/NEJMra1407550 – ident: CIT0036 doi: 10.1093/nar/gkv1100 – ident: CIT0037 doi: 10.1016/j.chroma.2019.04.037 – ident: CIT0033 doi: 10.1016/j.jviromet.2017.11.012 – ident: CIT0020 doi: 10.1038/nm0202-121 – ident: CIT0038 doi: 10.7150/ijbs.31957 – ident: CIT0001 doi: 10.1007/978-1-4939-0659-8_18 – ident: CIT0010 doi: 10.1016/j.ucl.2013.08.012 – ident: CIT0011 doi: 10.1055/s-0036-1571435 – ident: CIT0023 doi: 10.1073/pnas.251687998 – ident: CIT0002 doi: 10.1055/s-0034-1375184 – ident: CIT0029 doi: 10.1002/j.1939-4640.2004.tb02780.x – ident: CIT0030 doi: 10.1016/j.juro.2015.03.076 – ident: CIT0034 doi: 10.1101/pdb.prot093419 – ident: CIT0040 doi: 10.1186/gb-2007-8-2-r24 – ident: CIT0015 doi: 10.1002/med.20225 – ident: CIT0022 doi: 10.1074/jbc.274.17.11593 – ident: CIT0013 doi: 10.2174/1573413052953110 – ident: CIT0018 doi: 10.3109/1061186X.2011.572974 – ident: CIT0028 doi: 10.1007/s13346-011-0039-x – ident: CIT0019 doi: 10.1080/1061186X.2018.1531419 – volume: 2 start-page: 106 issue: 2 year: 2013 ident: CIT0004 publication-title: Transl Androl Urol – ident: CIT0021 doi: 10.1038/nm1048 – ident: CIT0009 doi: 10.1038/nrurol.2011.26 – volume-title: Drug elimination year: 2022 ident: CIT0044 – volume: 1 start-page: 259 issue: 3 year: 2007 ident: CIT0003 publication-title: Biol Targets Ther – ident: CIT0025 doi: 10.1371/journal.pone.0012252 – volume: 108 start-page: 395 year: 2005 ident: CIT0032 publication-title: Methods Mol Med – ident: CIT0027 doi: 10.1016/j.drudis.2014.10.003 – ident: CIT0005 doi: 10.1002/ijc.20931 – ident: CIT0039 doi: 10.1093/bioinformatics/btab203 – ident: CIT0035 doi: 10.1007/978-1-4939-2020-4_17 |
| SSID | ssj0013610 |
| Score | 2.375911 |
| Snippet | The testicle, an organ privileged with immunity because of Blood-Testis Barrier (BTB), poses a major impediment to developing and delivering drugs to the... |
| SourceID | proquest pubmed crossref informaworld |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 390 |
| SubjectTerms | Animals biopanning drug targeting Homing peptides Humans Male Mice Peptide Library Peptides - chemistry phage display Sertoli cell Sertoli Cells Testicular Neoplasms testis |
| Title | Identification and validation of Sertoli cell homing peptides as molecular steering for testis targeted drug delivery |
| URI | https://www.tandfonline.com/doi/abs/10.1080/1061186X.2022.2164007 https://www.ncbi.nlm.nih.gov/pubmed/36604336 https://www.proquest.com/docview/2761976235 |
| Volume | 31 |
| WOSCitedRecordID | wos000912744600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1029-2330 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013610 issn: 1061-186X databaseCode: TFW dateStart: 19930101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9swDBa2Yodd9t6abis4YOip7mzJka3jMCzYYShyyLDcDNmitgJpXMTOgPz7kpbcrIeih-3oA22ZIkVSJD8K8VGirb3RZaKasklybU1ilbWJzBWJs-RM0wCZ_704Py-XSzOP1YRdLKvkGNoHoIjhrGbltnU3VsR94igmK_WSojspzyQ5_KGfnDx7lvHF7Oc-j6AjHoHOEiYZe3juesst63QLu_RuD3SwRLOn_-Efnokn0Q2Fz0FunosHuH4hTuYBx3p3Cot9W1Z3Cicw3yNc716KbWjv9fG-D2gVQBJ7EeYzQeuBjqC-XV0A5wXgd3tJBhKuuIDGYQe2g8txKi-QlA1oiEBMgJ4xPzoI5enowG22v8DhiotHdq_Ej9nXxZdvSZzfkDRkGvvEqcJqZxqJxnl2TdHnKeYmM4WjwNSR8mPRpI3UdV2awtIDZ0nRp1M3NSWq1-Jg3a7xUEBt6dyZlib1GnNfp1ZbiVJ7zJBodToR-bhvVRPBzXnGxqrKIgbqyPCKGV5Fhk_E2Q3ZVUD3uI_A_C0UVT9cq_gwA6VS99B-GCWoIh3mDbBrbLddJfkuiTRDTSfiTRCtm-UorRljTh_9w5ffisf0qDgJJrN34qDfbPG9eNT8oS3dHIuHxbI8HvTmGgRjE78 |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQQYILb8oChUFCPTUlsRMnPiLUVRHLqodF7M1yYptW2m6qTbbS_vvOxEm3PVQ9wDGKJo_xjGc8j28Y-8KdKb2SRSSqoopSaVRkhDERTwWKM6dMUweZP8mn02I-Vzd7Yaisks7QPgBFdHs1KTcFo4eSuK90jEkKOcfjHeeHHD3-rqH8YYa2lsr6ZuM_20yC7BEJZBIRzdDFc9djbtmnW-ild_ugnS0aP_sff_GcPe09UfgWROcFe-CWL9n-SYCy3hzAbNuZ1RzAPpxsQa43r9g6dPj6PuQH-BmAQnsWRjRB7QF3obZenAGlBuC0PkcbCRdUQ2NdA6aB82EwL6CgdYCIgFyAlmA_GggV6s6CXa3_gnULqh_ZvGa_x0ez78dRP8IhqtA6tpEVuZFWVdwp68k7dT6NXaoSlVs8m1rUf5dXccVlWRYqN3hBiVLn48xmqnDiDdtZ1kv3lkFpcOvJChV76VJfxkYa7rj0LnFIK-MRS4eF01WPb05jNhY66WFQB4ZrYrjuGT5ih9dkFwHg4z4CdVMqdNtFVnwYg6LFPbSfBxHSqMa0AGbp6nWjOYWTUDlENmK7QbauP0dISTBz8t0_vPkTe3w8-zXRkx_Tn-_ZE7wlKCfGkw9sp12t3R57VF3i8q4-dupzBc8rFvg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9swDBaGbhh22fuRPTlg6KnubMmRreOwLdiwIsghw3ITZIvaCqRxEDsF8u9LWXKzHooetqNh0A-KFEmR_MjYB46mckqWiajLOsmlUYkRxiQ8FyTO3Geaesj8k2I6LRcLNYvVhG0sq_QxtAtAEf1e7ZV7bd1QEffRRzFZKRcU3XF-zMnh7_vJb_fgWCTS88mvfSJBRkACmSWeZmjiue4xV8zTFfDS613Q3hRNHvyHn3jI7kc_FD4FwXnEbuHqMTucBSDr3RHM931Z7REcwmwPcb17wrahv9fFAz-grwAS2dMwoAkaB7QHdc3yFHxiAP40Z2QhYe0raCy2YFo4G8byAolZD4cIxAToPOhHC6E-HS3YzfY3WFz66pHdU_Zz8nX--VsSBzgkNdnGLrGiMNKqmqOyzvum6PIUc5WpwlJkakn7sajTmsuqKlVh6MKnSdGlYztWJYpn7GDVrPAFg8rQxjMuVeok5q5KjTQcuXSYIdHKdMTyYd10HdHN_ZCNpc4iCOrAcO0ZriPDR-z4kmwd4D1uIlB_C4Xu-nMVF4agaHED7ftBgjQpsV8As8Jm22ruD5NINcR4xJ4H0br8HCGlB5mTL__hze_Y3dmXiT75Pv3xit2jO8InxHj2mh10my2-YXfqc1rdzdteeS4ARHkVnA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+and+validation+of+Sertoli+cell+homing+peptides+as+molecular+steering+for+testis+targeted+drug+delivery&rft.jtitle=Journal+of+drug+targeting&rft.au=Jirwankar%2C+Yugandhara&rft.au=Dighe%2C+Vikas&rft.date=2023-04-21&rft.issn=1029-2330&rft.eissn=1029-2330&rft.volume=31&rft.issue=4&rft.spage=390&rft_id=info:doi/10.1080%2F1061186X.2022.2164007&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1061-186X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1061-186X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1061-186X&client=summon |